NCT01287988View on ClinicalTrials.gov

Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies

CompletedOBSERVATIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Symptomatic Vitreomacular Adhesion
Interventions
DRUG

ocriplasmin

Subjects were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study TG-MV-006 or TG-MV-007

DRUG

placebo

Subjects were exposed to a single intravitreal injection of placebo in a previous phase III study TG-MV-006 or TG-MV-007

Trial Locations (2)

Unknown

Retinal Consultants of Houston, Houston

Universitaire Ziekenhuizen K.U. Leuven, Leuven

Sponsors

Lead Sponsor

ThromboGenics
All Listed Sponsors
lead

ThromboGenics

INDUSTRY

NCT01287988 - Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies | Biotech Hunter | Biotech Hunter